Search

Your search keyword '"A. Weizer"' showing total 2,594 results
Start Over Author "A. Weizer"
2,594 results on '"A. Weizer"'

1. Integrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine Response

Author

Merrill, Nathan M., Kaffenberger, Samuel D., Bao, Liwei, Vandecan, Nathalie, Goo, Laura, Apfel, Athena, Cheng, Xu, Qin, Zhaoping, Liu, Chia-Jen, Bankhead, Armand, Wang, Yin, Kathawate, Varun, Tudrick, Lila, Serhan, Habib A., Farah, Zackariah, Ellimoottil, Chad, Hafez, Khaled S., Herrel, Lindsey A., Montgomery, Jeffrey S., Morgan, Todd M., Salami, Simpa S., Weizer, Alon Z., Ulintz, Peter J., Day, Mark L., Soellner, Matthew B., Palmbos, Phillip L., Merajver, Sofia D., and Udager, Aaron M.

Published
2024
Full Text
View/download PDF

3. The protective role of postpartum resilience on anxiety rates of Brazilian mothers during the COVID-19 pandemic

Author

Carolina Coelho Scholl, Fernanda Teixeira Coelho, Bárbara Borges Rubin, Caroline Nickel Ávila, Isabela Petry, Kathreim Macedo da Rosa, Rayssa da Luz Martins, Victória Duquia da Silva, Mariana Weizer, Jéssica Puchalski Trettim, Mariana Bonati de Matos, Ricardo Tavares Pinheiro, and Luciana de Avila Quevedo

Subjects
COVID-19, mental health, maternal anxiety, anxiety, resilience, psychological, Psychiatry, RC435-571
Abstract

ABSTRACT Objective: We evaluated the protective effect of postpartum resilience (measured before the pandemic onset) on the prevalence of moderate to severe anxiety symptoms during the coronavirus disease (COVID-19) pandemic. Methods: The sample included 589 mothers from a longitudinal study in southern Brazil. Three months after delivery we assessed maternal resilience through the Resilience Scale (RS). The Generalized Anxiety Disorders 7-item (GAD-7) was used to assess anxiety symptoms during the COVID-19 pandemic. Results: The prevalence of severe to moderate anxiety symptoms in this sample was 28.4% (95% CI: 25.0; 32.0). Resilience showed to be a protective factor against moderate to severe anxiety symptoms during the pandemic (OR: 0.98; p

Published
2023
Full Text
View/download PDF

4. Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Followup.

Author

Venkatramani, Vivek, Reis, Isildinha M, Castle, Erik P, Gonzalgo, Mark L, Woods, Michael E, Svatek, Robert S, Weizer, Alon Z, Konety, Badrinath R, Tollefson, Mathew, Krupski, Tracey L, Smith, Norm D, Shabsigh, Ahmad, Barocas, Daniel A, Quek, Marcus L, Dash, Atreya, Kibel, Adam S, Pruthi, Raj S, Montgomery, Jeffrey Scott, Weight, Christopher J, Sharp, David S, Chang, Sam S, Cookson, Michael S, Gupta, Gopal N, Gorbonos, Alex, Uchio, Edward M, Skinner, Eila, Soodana-Prakash, Nachiketh, Becerra, Maria F, Swain, Sanjaya, Kendrick, Kerri, Smith, Joseph A, Thompson, Ian M, and Parekh, Dipen J

Subjects
Prevention, Cancer, Clinical Trials and Supportive Activities, Comparative Effectiveness Research, Clinical Research, Aged, Cystectomy, Disease Progression, Female, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Robotic Surgical Procedures, Survival Rate, United States, Urinary Bladder Neoplasms, bladder neoplasms, cystectomy, neoplasm recurrence, robotic surgical procedures, mortality
Abstract

PurposeThe RAZOR (Randomized Open versus Robotic Cystectomy) trial revealed noninferior 2-year progression-free survival for robotic radical cystectomy. This update was performed with extended followup for 3 years to determine potential differences between the approaches. We also report 3-year overall survival and sought to identify factors predicting recurrence, and progression-free and overall survival.Materials and methodsWe analyzed the per protocol population of 302 patients from the RAZOR study. Cumulative recurrence was estimated using nonbladder cancer death as the competing risk event and the Gray test was applied to assess significance in differences. Progression-free survival and overall survival were estimated by the Kaplan-Meier method and compared with the log rank test. Predictors of outcomes were determined by Cox proportional hazard analysis.ResultsEstimated progression-free survival at 36 months was 68.4% (95% CI 60.1-75.3) and 65.4% (95% CI 56.8-72.7) in the robotic and open groups, respectively (p=0.600). At 36 months overall survival was 73.9% (95% CI 65.5-80.5) and 68.5% (95% CI 59.8-75.7) in the robotic and open groups, respectively (p=0.334). There was no significant difference in the cumulative incidence rates of recurrence (p=0.802). Patient age greater than 70 years, poor performance status and major complications were significant predictors of 36-month progression-free survival. Stage and positive margins were significant predictors of recurrence, and progression-free and overall survival. Surgical approach was not a significant predictor of any outcome.ConclusionsThis analysis showed no difference in recurrence, 3-year progression-free survival or 3-year overall survival for robotic vs open radical cystectomy. It provides important prospective data on the oncologic efficacy of robotic radical cystectomy and high level data for patient counseling.

Published
2020

7. Reply by Authors

Author

Hijazi, Mahmoud A., Prebay, Zachary J., Johnson, Anna, Wilder, Samantha, Patel, Amit, Mehra, Rohit, Montie, James E., Noyes, Sabrina L., Mirza, Mahin, Jafri, Mohammad, Weizer, Alon, Sarle, Richard, Ghani, Khurshid R., Rogers, Craig, and Lane, Brian R.

Published
2023
Full Text
View/download PDF

8. Reducing Injection-Related Safety Events in Retina Clinics

Author

John DA, Hansemann B, Lieu P, and Weizer J

Subjects
adverse event, healthcare failure mode and effect analysis, intravitreal injections, patient safety, Ophthalmology, RE1-994
Abstract

Denise A John, Beth Hansemann, Philip Lieu, Jennifer Weizer Department of Ophthalmology, University of Michigan, Ann Arbor, MI, USACorrespondence: Denise A John, Department of Ophthalmology, University of Michigan, 1000 Wall Street, Ann Arbor, MI, 48105, USA, Tel +1-615-545-8940, Fax +1-734-647-3555, Email denisejo@med.umich.eduPurpose: At the Kellogg Eye Center, we identified a series of injection-related patient safety events that led to a systematic review and redesign of our intravitreal injection protocol. The objective was to reduce injection-related patient safety events to zero.Methods: A retroactive review, using the Healthcare Failure Mode and Effect Analysis model as a guide, was performed on our process for delivering intravitreal injections to identify potential failure modes and their impact.Results: The total number of injection-related safety events was 1 in 2017 and 16 in 2018 at baseline. Potential vulnerabilities identified included errors in communication, patient identification, clinical documentation, and medication orders. The injection protocol was redesigned. After implementation, there were zero injection-related safety events in all Kellogg Eye Center Retina clinics for the subsequent 18-month follow-up period.Conclusion: It is possible to redesign and implement an intravitreal injection protocol to reduce the rate of safety events in a large academic eye center.Keywords: adverse event, healthcare failure mode and effect analysis, intravitreal injections, patient safety

Published
2022

9. Computerized Decision Support for Bladder Cancer Treatment Response Assessment in CT Urography: Effect on Diagnostic Accuracy in Multi-Institution Multi-Specialty Study

Author

Di Sun, Lubomir Hadjiiski, Ajjai Alva, Yousef Zakharia, Monika Joshi, Heang-Ping Chan, Rohan Garje, Lauren Pomerantz, Dean Elhag, Richard H. Cohan, Elaine M. Caoili, Wesley T. Kerr, Kenny H. Cha, Galina Kirova-Nedyalkova, Matthew S. Davenport, Prasad R. Shankar, Isaac R. Francis, Kimberly Shampain, Nathaniel Meyer, Daniel Barkmeier, Sean Woolen, Phillip L. Palmbos, Alon Z. Weizer, Ravi K. Samala, Chuan Zhou, and Martha Matuszak

Subjects
observer study, computer-aided diagnosis, bladder cancer, treatment response, Computer applications to medicine. Medical informatics, R858-859.7
Abstract

This observer study investigates the effect of computerized artificial intelligence (AI)-based decision support system (CDSS-T) on physicians’ diagnostic accuracy in assessing bladder cancer treatment response. The performance of 17 observers was evaluated when assessing bladder cancer treatment response without and with CDSS-T using pre- and post-chemotherapy CTU scans in 123 patients having 157 pre- and post-treatment cancer pairs. The impact of cancer case difficulty, observers’ clinical experience, institution affiliation, specialty, and the assessment times on the observers’ diagnostic performance with and without using CDSS-T were analyzed. It was found that the average performance of the 17 observers was significantly improved (p = 0.002) when aided by the CDSS-T. The cancer case difficulty, institution affiliation, specialty, and the assessment times influenced the observers’ performance without CDSS-T. The AI-based decision support system has the potential to improve the diagnostic accuracy in assessing bladder cancer treatment response and result in more consistent performance among all physicians.

Published
2022
Full Text
View/download PDF

11. Effect of computerized decision support on diagnostic accuracy and intra-observer variability in multi-institutional observer performance study for bladder cancer treatment response assessment in CT urography.

Author

Di Sun, Lubomir M. Hadjiiski, Rohan Garje, Yousef Zakharia, Lauren Pomerantz, Monika Joshi, Ajjai Alva, Heang-Ping Chan, Richard H. Cohan, Elaine M. Caoili, Kenny H. Cha, Galina Kirova-Nedyalkova, Matthew S. Davenport, Prasad R. Shankar, Isaac R. Francis, Kimberly Shampain, Nathaniel Meyer, Daniel Barkmeier, Sean Woolen, Phillip L. Palmbos, Alon Z. Weizer, Ravi K. Samala, Chuan Zhou 0002, and Martha M. Matuszak

Published
2022
Full Text
View/download PDF

13. The Feasibility and Impact of a Presurgical Exercise Intervention Program (Prehabilitation) for Patients Undergoing Cystectomy for Bladder Cancer

Author

Kaye, Deborah R., Schafer, Christine, Thelen-Perry, Steven, Parker, Christine, Iglay-Reger, Heidi, Daignault-Newton, Stephanie, Qin, Yongmei, Morgan, Todd M., Weizer, Alon Z., Kaffenberger, Samuel D., Herrel, Lindsey A., Hafez, Khaled S., Lee, Cheryl T., Skolarus, Ted A., Englesbe, Michael J., and Montgomery, Jeffrey S.

Published
2020
Full Text
View/download PDF

16. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial

Author

Kleinmann, Nir, Matin, Surena F, Pierorazio, Phillip M, Gore, John L, Shabsigh, Ahmad, Hu, Brian, Chamie, Karim, Godoy, Guilherme, Hubosky, Scott, Rivera, Marcelino, O'Donnell, Michael, Quek, Marcus, Raman, Jay D, Knoedler, John J, Scherr, Douglas, Stern, Joshua, Weight, Christopher, Weizer, Alon, Woods, Michael, Kaimakliotis, Hristos, Smith, Angela B, Linehan, Jennifer, Coleman, Jonathan, Humphreys, Mitchell R, Pak, Raymond, Lifshitz, David, Verni, Michael, Adibi, Mehrad, Amin, Mahul B, Seltzer, Elyse, Klein, Ifat, Konorty, Marina, Strauss-Ayali, Dalit, Hakim, Gil, Schoenberg, Mark, and Lerner, Seth P

Published
2020
Full Text
View/download PDF

17. PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy

Author

Yeh, Hsin-Chih, Margulis, Vitaly, Singla, Nirmish, Hernandez, Elizabeth, Panwar, Vandana, Woldu, Solomon L., Karam, Jose A., Wood, Christopher G., Weizer, Alon Z., Raman, Jay D., Remzi, Mesut, Rioux-Leclercq, Nathalie, Haitel, Andrea, Roscigno, Marco, Bolenz, Christian, Bensalah, Karim, Li, Ching-Chia, Ke, Hung-Lung, Li, Wei-Ming, Lee, Hsiang-Ying, Rapoport, Leonid M., Lotan, Yair, Kapur, Payal, Shariat, Shahrokh F., Hsieh, Jer-Tsong, and Wu, Wen-Jeng

Published
2020
Full Text
View/download PDF

19. A Two-Year Longitudinal Assessment of Ophthalmologists Perceptions after Implementing an Electronic Health Record System.

Author

Ehrlich, Joshua, Michelotti, Monica, Blachley, Taylor, Couper, Mick, Greenberg, Grant, Kileny, Sharon, Branford, Greta, Hanauer, David, Weizer, Jennifer, and Zheng, Kai

Subjects
Ophthalmology, clinical documentation and communications, electronic health records and systems, implementation and deployment, testing and evaluation, Adult, Aged, Attitude of Health Personnel, Electronic Health Records, Female, Humans, Longitudinal Studies, Male, Middle Aged, Ophthalmologists, Surveys and Questionnaires
Abstract

OBJECTIVES: To understand the attitudes and perceptions of ophthalmologists toward an electronic health record (EHR) system, before and after its clinical implementation. METHODS: Ophthalmologists at a single large academic ophthalmology department were surveyed longitudinally before and after implementation of a new EHR system. The survey measured ophthalmologists attitudes toward implementation of a new EHR. Questions focused on satisfaction, efficiency, and documentation. All attending physicians (between 56 and 61 at various time points) in the University of Michigan Department of Ophthalmology and Visual Sciences were surveyed. We plotted positive responses to survey questions and assessed whether perceptions followed a J-curve with an initial decrease followed by an increase surpassing pre-implementation levels. RESULTS: Survey responses were received from 32 (52%) ophthalmologists pre-implementation, and 28 (46%) at 3 months, 35 (57%) at 7 months, 40 (71%) at 13 months and 39 (67%) at 24 months post-implementation. After EHR implementation respondents were more likely to express concerns about their ability to create high-quality documentation (p

Published
2016

22. Circulating Tumor Cells as Potential Biomarkers in Bladder Cancer

Author

Alva, Ajjai, Friedlander, Terence, Clark, Melanie, Huebner, Tamara, Daignault, Stephanie, Hussain, Maha, Lee, Cheryl, Hafez, Khaled, Hollenbeck, Brent, Weizer, Alon, Premasekharan, Gayatri, Tran, Tony, Fu, Christine, Ionescu-Zanetti, Cristian, Schwartz, Michael, Fan, Andrea, and Paris, Pamela

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Clinical Research, Urologic Diseases, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Neoadjuvant Therapy, Neoplastic Cells, Circulating, Pilot Projects, Prospective Studies, Urinary Bladder Neoplasms, urinary bladder neoplasms, neoplastic cells, circulating, neoadjuvant therapy, pathology, molecular, genomics, circulating, molecular, neoplastic cells, pathology, Clinical Sciences, Urology & Nephrology, Clinical sciences
Abstract

PurposeWe explored the diagnostic use of circulating tumor cells in patients with neoadjuvant bladder cancer using enumeration and next generation sequencing.Materials and methodsA total of 20 patients with bladder cancer who were eligible for cisplatin based neoadjuvant chemotherapy were enrolled in an institutional review board approved study. Subjects underwent blood draws at baseline and after 1 cycle of chemotherapy. A total of 11 patients with metastatic bladder cancer and 13 healthy donors were analyzed for comparison. Samples were enriched for circulating tumor cells using the novel IsoFlux™ System microfluidic collection device. Circulating tumor cell counts were analyzed for repeatability and compared with Food and Drug Administration cleared circulating tumor cells. Circulating tumor cells were also analyzed for mutational status using next generation sequencing.ResultsMedian circulating tumor cell counts were 13 at baseline and 5 at followup in the neoadjuvant group, 29 in the metastatic group and 2 in the healthy group. The concordance of circulating tumor cell levels, defined as low-fewer than 10, medium-11 to 30 and high-greater than 30, across replicate tubes was 100% in 15 preparations. In matched samples the IsoFlux test showed 10 or more circulating tumor cells in 4 of 9 samples (44%) while CellSearch® showed 0 of 9 (0%). At cystectomy 4 months after baseline all 3 patients (100%) with medium/high circulating tumor cell levels at baseline and followup had unfavorable pathological stage disease (T1-T4 or N+). Next generation sequencing analysis showed somatic variant detection in 4 of 8 patients using a targeted cancer panel. All 8 cases (100%) had a medium/high circulating tumor cell level with a circulating tumor cell fraction of greater than 5% purity.ConclusionsThis study demonstrates a potential role for circulating tumor cell assays in the management of bladder cancer. The IsoFlux method of circulating tumor cell detection shows increased sensitivity compared with CellSearch. A next generation sequencing assay is presented with sufficient sensitivity to detect genomic alterations in circulating tumor cells.

Published
2015

24. Diagnostic Accuracy of CT for Prediction of Bladder Cancer Treatment Response with and without Computerized Decision Support

Author

Cha, Kenny H., Hadjiiski, Lubomir M., Cohan, Richard H., Chan, Heang-Ping, Caoili, Elaine M., Davenport, Matthew S., Samala, Ravi K., Weizer, Alon Z., Alva, Ajjai, Kirova-Nedyalkova, Galina, Shampain, Kimberly, Meyer, Nathaniel, Barkmeier, Daniel, Woolen, Sean, Shankar, Prasad R., Francis, Isaac R., and Palmbos, Phillip

Published
2019
Full Text
View/download PDF

25. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer

Author

Valenberg, F. Johannes P. van, Hiar, Andrew M., Wallace, Ellen, Bridge, Julia A., Mayne, Donna J., Beqaj, Safedin, Sexton, Wade J., Lotan, Yair, Weizer, Alon Z., Jansz, Godfrey K., Stenzl, Arnulf, Danella, John F., Shepard, Barry, Cline, Kevin J., Williams, Michael B., Montgomery, Scott, David, Richard D., Harris, Richard, Klein, Eric W., Bradford, Timothy J., Wolk, Fred N., Westenfelder, Karl R., Trainer, Andrew F., Richardson, Timothy A., Egerdie, Russell B., Goldfarb, Bernard, Zadra, Joseph A., Ge, Sijian, Zhao, Suling, Simon, Iris M., Campbell, Scott A., Rhees, Brian, Bates, Michael P., Higuchi, Russell G., and Witjes, J. Alfred

Published
2019
Full Text
View/download PDF

26. Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma

Author

Simon, Caroline T., Skala, Stephanie L., Weizer, Alon Z., Ambani, Sapan N., Chinnaiyan, Arul M., Palapattu, Ganesh, Hafez, Khaled, Magers, Martin J., Kaffenberger, Samuel D., Spratt, Daniel E., Montgomery, Jeffrey S., Morgan, Todd M., Udager, Aaron M., Lew, Madelyn, and Mehra, Rohit

Published
2019
Full Text
View/download PDF

31. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications

Author

Hovelson, Daniel H., Udager, Aaron M., McDaniel, Andrew S., Grivas, Petros, Palmbos, Phillip, Tamura, Shuzo, Lazo de la Vega, Lorena, Palapattu, Ganesh, Veeneman, Brendan, El-Sawy, Layla, Sadis, Seth E., Morgan, Todd M., Montgomery, Jeffrey S., Weizer, Alon Z., Day, Kathleen C., Neamati, Nouri, Liebert, Monica, Keller, Evan T., Day, Mark L., Mehra, Rohit, and Tomlins, Scott A.

Published
2018
Full Text
View/download PDF

34. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial

Author

Parekh, Dipen J, Reis, Isildinha M, Castle, Erik P, Gonzalgo, Mark L, Woods, Michael E, Svatek, Robert S, Weizer, Alon Z, Konety, Badrinath R, Tollefson, Mathew, Krupski, Tracey L, Smith, Norm D, Shabsigh, Ahmad, Barocas, Daniel A, Quek, Marcus L, Dash, Atreya, Kibel, Adam S, Shemanski, Lynn, Pruthi, Raj S, Montgomery, Jeffrey Scott, Weight, Christopher J, Sharp, David S, Chang, Sam S, Cookson, Michael S, Gupta, Gopal N, Gorbonos, Alex, Uchio, Edward M, Skinner, Eila, Venkatramani, Vivek, Soodana-Prakash, Nachiketh, Kendrick, Kerri, Smith, Joseph A, Jr, and Thompson, Ian M

Published
2018
Full Text
View/download PDF

35. Outcomes of Intracorporeal Urinary Diversion after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium

Author

Wagner, Andrew, Saar, Matthias, Stockle, Michael, Redorta, Joan Palou, Richstone, Lee, Badani, Ketan, Scherr, Douglas, Khan, Hijab, Gaboardi, Franco, Rha, Koon-Ho, Kawa, Omar, Tan, Wei Shen, Schanne, Francis, Polakis, Vassilis, Weizer, Alon, Maatman, Thomas J., Pini, Giovannalberto, Peak, Taylor C., Kibel, Adam, Yuh, Bertram, Hussein, Ahmed A., May, Paul R., Jing, Zhe, Ahmed, Youssef E., Wijburg, Carl J., Canda, Abdulla Erdem, Dasgupta, Prokar, Shamim Khan, Mohammad, Menon, Mani, Peabody, James O., Hosseini, Abolfazl, Kelly, John, Mottrie, Alexandre, Kaouk, Jihad, Hemal, Ashok, Wiklund, Peter, and Guru, Khurshid A.

Published
2018
Full Text
View/download PDF

36. Development of a 90-Minute Integrated Noninvasive Urinary Assay for Bladder Cancer Detection

Author

Wallace, Ellen, Higuchi, Russell, Satya, Malini, McCann, Leena, Sin, Mandy L.Y., Bridge, Julia A., Wei, Huilin, Zhang, Jun, Wong, Edith, Hiar, Andrew, Mach, Kathleen E., Scherr, Douglas, Egerdie, R. Blair, Ohta, Shoichiro, Sexton, Wade J., Meng, Maxwell V., Weizer, Alon Z., Woods, Michael, Jansz, G. Kenneth, Zadra, Joseph, Lotan, Yair, Goldfarb, Bernard, and Liao, Joseph C.

Published
2018
Full Text
View/download PDF

37. Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study

Author

Aydin, Ahmet M., Singla, Nirmish, Panwar, Vandana, Woldu, Solomon L., Freifeld, Yuval, Wood, Christopher G., Karam, Jose A., Weizer, Alon Z., Raman, Jay D., Remzi, Mesut, Rioux-Leclercq, Nathalie, Haitel, Andrea, Roscigno, Marco, Bolenz, Christian, Bensalah, Karim, Westerman, Mary E., Sagalowsky, Arthur I., Shariat, Shahrokh F., Lotan, Yair, Bagrodia, Aditya, Kapur, Payal, Margulis, Vitaly, and Krabbe, Laura-Maria

Published
2019
Full Text
View/download PDF

40. Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy

Author

Rieken, Malte, Shariat, Shahrokh F., Karam, Jose A., Foerster, Beat, Khani, Francesca, Gust, Kilian, Abufaraj, Mohammad, Wood, Christopher G., Weizer, Alon Z., Raman, Jay D., Guo, Charles C., Rioux-Leclercq, Nathalie, Haitel, Andrea, Bensalah, Karim, Lotan, Yair, Bachmann, Alexander, De Marzo, Angelo M., Robinson, Brian D., and Margulis, Vitaly

Published
2017
Full Text
View/download PDF

41. Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma

Author

Krabbe, Laura-Maria, Heitplatz, Barbara, Preuss, Sina, Hutchinson, Ryan C., Woldu, Solomon L., Singla, Nirmish, Boegemann, Martin, Wood, Christopher G., Karam, Jose A., Weizer, Alon Z., Raman, Jay D., Remzi, Mesut, Rioux-Leclercq, Nathalie, Haitel, Andrea, Rapoport, Leonid M., Glybochko, Peter V., Roscigno, Marco, Bolenz, Christian, Bensalah, Karim, Sagalowsky, Arthur I., Shariat, Shahrokh F., Lotan, Yair, Xylinas, Evanguelos, and Margulis, Vitaly

Published
2017
Full Text
View/download PDF

42. Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma

Author

Skala, Stephanie L., Liu, Tzu-Ying, Udager, Aaron M., Weizer, Alon Z., Montgomery, Jeffrey S., Palapattu, Ganesh S., Siddiqui, Javed, Cao, Xuhong, Fields, Kristina, Abugharib, Ahmed E., Soliman, Moaaz, Hafez, Khaled S., Miller, David, Lee, Cheryl T., Alva, Ajjai, Chinnaiyan, Arul M., Morgan, Todd M., Spratt, Daniel E., Jiang, Hui, and Mehra, Rohit

Published
2017
Full Text
View/download PDF

49. Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma

Author

Krabbe, Laura-Maria, Eminaga, Okyaz, Shariat, Shahrokh F., Hutchinson, Ryan C., Lotan, Yair, Sagalowsky, Arthur I., Raman, Jay D., Wood, Christopher G., Weizer, Alon Z., Roscigno, Marco, Montorsi, Francesco, Bolenz, Christian, Novara, Giacomo, Kikuchi, Eiji, Fajkovic, Harun, Rapoport, Leonid M., Glybochko, Peter V., Zigeuner, Richard, Remzi, Mesut, Bensalah, Karim, Kassouf, Wassim, and Margulis, Vitaly

Published
2017
Full Text
View/download PDF

50. Mapping standard ophthalmic outcome sets to metrics currently reported in eight eye hospitals

Author

Monica Michelotti, Dirk F. de Korne, Jennifer S. Weizer, Paul P. Lee, Declan Flanagan, Simon P. Kelly, Anne Odergren, Sukhpal S. Sandhu, Charity Wai, Niek Klazinga, Aravind Haripriya, Joshua D. Stein, and Melanie Hingorani

Subjects
Outcomes, Measurement, Benchmarking, Quality improvement, Ophthalmology, RE1-994
Abstract

Abstract Background To determine alignment of proposed international standard outcomes sets for ophthalmic conditions to metrics currently reported by eye hospitals. Methods Mixed methods comparative benchmark study, including eight eye hospitals in Australia, India, Singapore, Sweden, U.K., and U.S. All are major international tertiary care and training centers in ophthalmology. Main outcome measure is consistency of ophthalmic outcomes measures reported. Results International agreed standard outcomes (ICHOM) sets are available for cataract surgery (10 metrics) and macular degeneration (7 metrics). The eight hospitals reported 22 different metrics for cataract surgery and 2 for macular degeneration, which showed only limited overlap with the proposed ICHOM metrics. None of the hospitals reported patient reported visual functioning or vision-related quality of life outcomes measures (PROMs). Three hospitals (38%) reported rates for uncomplicated cataract surgeries only. There was marked variation in how and at what point postoperatively visual outcomes following cataract, cornea, glaucoma, strabismus and oculoplastics procedures were reported. Seven (87.5%) measured post-operative infections and four (50%) measured 30 day unplanned reoperation rates. Conclusions Outcomes reporting for ophthalmic conditions currently widely varies across hospitals internationally and does not include patient-reported outcomes. Reaching consensus on measures and consistency in data collection will allow meaningful comparisons and provide an evidence base enabling improved sharing of “best practices” to improve eye care globally. Implementation of international standards is still a major challenge and practice-based knowledge on measures should be one of the inputs of the international standardization process.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results